Market Place
Sourcing Support
All News #Library
Rare Diseases
Capricor Therapeutics Unveils HOPE-3 Phase 3 Results At AAN 2026
22 Apr 2026 //
GLOBENEWSWIRE
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data
12 Mar 2026 //
GLOBENEWSWIRE
Capricor Therapeutics Sets New PDUFA Date For Deramiocel BLA
11 Mar 2026 //
GLOBENEWSWIRE
Capricor Announces Late-Breaking Presentation at 2026 MDA
24 Feb 2026 //
GLOBENEWSWIRE
Sarepta Challenges Prompt Search For Advancements In DMD Therapy
09 Feb 2026 //
BIOSPACE
Capricor & Parent Project Muscular Dystrophy Host Webinar
16 Dec 2025 //
GLOBENEWSWIRE
Capricor Eyes Nod for Duchenne Therapy After Success in Study
03 Dec 2025 //
GLOBENEWSWIRE
Capricor Publishes Study on Deramiocel MOA and Potency Assay
03 Nov 2025 //
GLOBENEWSWIRE
Capricor Therapeutics Updates Deramiocel Program For DMD
25 Sep 2025 //
GLOBENEWSWIRE
Rare Disease Experts See Futility In FDA`s Proposed Framework
22 Sep 2025 //
BIOSPACE
Capricor Respond to FDA`s Complete Response Letter for Deramiocel
09 Sep 2025 //
GLOBENEWSWIRE
Capricor Therapeutics: Positive 4-Year Data from HOPE-2 Study
20 Jun 2025 //
GLOBENEWSWIRE
Capricor Gets Orphan Drug Designation For BMD, Advances DMD
17 Jun 2025 //
GLOBENEWSWIRE
Capricor Therapeutic Show Long-Term Efficacy of Deramiocel for DMD
17 Mar 2025 //
GLOBENEWSWIRE
Capricor Granted Orphan Drug And ATMP Status For Deramiocel
20 Nov 2024 //
GLOBENEWSWIRE
CORRECTION: Capricor Therapeutics
25 Jun 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.